Cargando…

Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial

BACKGROUND: The weight-based dosing of ondansetron to reduce hypotension has never been investigated. The aim of this study is to determine the optimal dose of ondansetron required based on the patient’s weight to reduce hypotension following spinal anesthesia for cesarean section. METHODS: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Oofuvong, Maliwan, Kunapaisal, Thitikan, Karnjanawanichkul, Orarat, Dilokrattanaphijit, Nussara, Leeratiwong, Jaranya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094447/
https://www.ncbi.nlm.nih.gov/pubmed/30111294
http://dx.doi.org/10.1186/s12871-018-0568-7
_version_ 1783347817596583936
author Oofuvong, Maliwan
Kunapaisal, Thitikan
Karnjanawanichkul, Orarat
Dilokrattanaphijit, Nussara
Leeratiwong, Jaranya
author_facet Oofuvong, Maliwan
Kunapaisal, Thitikan
Karnjanawanichkul, Orarat
Dilokrattanaphijit, Nussara
Leeratiwong, Jaranya
author_sort Oofuvong, Maliwan
collection PubMed
description BACKGROUND: The weight-based dosing of ondansetron to reduce hypotension has never been investigated. The aim of this study is to determine the optimal dose of ondansetron required based on the patient’s weight to reduce hypotension following spinal anesthesia for cesarean section. METHODS: In this prospective, triple-blinded, parallel group, randomized controlled trial, a total of 228 pregnant women were randomized to receive either normal saline (group NS) or ondansetron 0.05 mg/kg (group O1) or ondansetron 0.1 mg/kg (group O2) intravenously 5 min before induction of spinal anesthesia. The incidence of hypotension, mean arterial pressure, heart rate, vasopressor requirements, and blood loss between the three groups were compared. Maternal and neonatal complications were also assessed. Changes in blood pressure and heart rate were compared using the generalized estimating equations method. RESULTS: Thirteen patients were excluded from the analysis because of no intervention (n = 12) and protocol violation (n = 1). Two hundred and fifteen patients remained for the intention-to-treat analysis. The incidence of hypotension in groups NS (n = 72), O1 (n = 71), and O2 (n = 72) were 81.9%, 84.5%, and 73.6%, respectively (P = 0.23). The episodes of hypotension before delivery (first 14 min after spinal anesthesia) were significantly higher in group O1 compared to NS (5 vs 2, P = 0.02). The overall heart rates throughout the operations were not different among the three groups. The ephedrine requirements and amount of blood loss were also similar among the three groups. The metoclopramide requirement was significantly lower in group O2 compared to group NS (2.8% vs 16.7%, P = 0.01). There were no serious adverse events in terms of maternal or neonatal complications. CONCLUSIONS: Ondansetron 0.05 mg/kg or 0.1 mg/kg administered before spinal anesthesia did not reduce the incidence of hypotension in this study. TRIAL REGISTRATION: Thai Clinical Trials Registry, TCTR 20160323001, 22 March 2016.
format Online
Article
Text
id pubmed-6094447
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60944472018-08-20 Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial Oofuvong, Maliwan Kunapaisal, Thitikan Karnjanawanichkul, Orarat Dilokrattanaphijit, Nussara Leeratiwong, Jaranya BMC Anesthesiol Research Article BACKGROUND: The weight-based dosing of ondansetron to reduce hypotension has never been investigated. The aim of this study is to determine the optimal dose of ondansetron required based on the patient’s weight to reduce hypotension following spinal anesthesia for cesarean section. METHODS: In this prospective, triple-blinded, parallel group, randomized controlled trial, a total of 228 pregnant women were randomized to receive either normal saline (group NS) or ondansetron 0.05 mg/kg (group O1) or ondansetron 0.1 mg/kg (group O2) intravenously 5 min before induction of spinal anesthesia. The incidence of hypotension, mean arterial pressure, heart rate, vasopressor requirements, and blood loss between the three groups were compared. Maternal and neonatal complications were also assessed. Changes in blood pressure and heart rate were compared using the generalized estimating equations method. RESULTS: Thirteen patients were excluded from the analysis because of no intervention (n = 12) and protocol violation (n = 1). Two hundred and fifteen patients remained for the intention-to-treat analysis. The incidence of hypotension in groups NS (n = 72), O1 (n = 71), and O2 (n = 72) were 81.9%, 84.5%, and 73.6%, respectively (P = 0.23). The episodes of hypotension before delivery (first 14 min after spinal anesthesia) were significantly higher in group O1 compared to NS (5 vs 2, P = 0.02). The overall heart rates throughout the operations were not different among the three groups. The ephedrine requirements and amount of blood loss were also similar among the three groups. The metoclopramide requirement was significantly lower in group O2 compared to group NS (2.8% vs 16.7%, P = 0.01). There were no serious adverse events in terms of maternal or neonatal complications. CONCLUSIONS: Ondansetron 0.05 mg/kg or 0.1 mg/kg administered before spinal anesthesia did not reduce the incidence of hypotension in this study. TRIAL REGISTRATION: Thai Clinical Trials Registry, TCTR 20160323001, 22 March 2016. BioMed Central 2018-08-15 /pmc/articles/PMC6094447/ /pubmed/30111294 http://dx.doi.org/10.1186/s12871-018-0568-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Oofuvong, Maliwan
Kunapaisal, Thitikan
Karnjanawanichkul, Orarat
Dilokrattanaphijit, Nussara
Leeratiwong, Jaranya
Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial
title Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial
title_full Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial
title_fullStr Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial
title_full_unstemmed Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial
title_short Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial
title_sort minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094447/
https://www.ncbi.nlm.nih.gov/pubmed/30111294
http://dx.doi.org/10.1186/s12871-018-0568-7
work_keys_str_mv AT oofuvongmaliwan minimaleffectiveweightbaseddosingofondansetrontoreducehypotensionincesareansectionunderspinalanesthesiaarandomizedcontrolledsuperioritytrial
AT kunapaisalthitikan minimaleffectiveweightbaseddosingofondansetrontoreducehypotensionincesareansectionunderspinalanesthesiaarandomizedcontrolledsuperioritytrial
AT karnjanawanichkulorarat minimaleffectiveweightbaseddosingofondansetrontoreducehypotensionincesareansectionunderspinalanesthesiaarandomizedcontrolledsuperioritytrial
AT dilokrattanaphijitnussara minimaleffectiveweightbaseddosingofondansetrontoreducehypotensionincesareansectionunderspinalanesthesiaarandomizedcontrolledsuperioritytrial
AT leeratiwongjaranya minimaleffectiveweightbaseddosingofondansetrontoreducehypotensionincesareansectionunderspinalanesthesiaarandomizedcontrolledsuperioritytrial